Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy.

Dr. John Migaly is a distinguished colorectal surgeon and Chief of the Division of Colorectal Surgery/Ravitch Division at Johns Hopkins Medicine. He specializes in the treatment of colorectal cancer, inflammatory bowel disease, and other benign and complex colorectal conditions. Dr. Migaly is committed to providing advanced, patient-centered care, often using minimally invasive techniques including laparoscopic and robotic surgery, to help reduce recovery time and improve outcomes. Dr. Migaly comes to Johns Hopkins Medicine from the Duke University School of Medicine, serving from 2008-2024 on the surgery faculty treating patients primarily through the Duke Cancer Institute. He was elevated to Program Director of the General Surgery Residency in 2012, and subsequently served as Vice Chair of Education until 2024. His work was critical to the success of the undergraduate, graduate, and continuing medical education missions at Duke Surgery. Dr. Migaly earned his B.A. in Biochemistry from New York University and his medical degree from the New York University School of Medicine. He completed surgical residency and a research fellowship at Temple University Health Sciences Center, and colorectal surgery fellowship at Cleveland Clinic Florida. Dr. Migaly’s career has been marked not only by a complex and high-volume clinical colon and rectal surgery practice, but also a commitment to research and education, supported by greater than 200 publications, book chapters, and presentations. His research is centered around improving practice patterns and outcomes in colorectal cancer care and recovery. His leadership and dedication to advancing the field of colorectal surgery is evident through his service on committees that shape how colorectal care is delivered nationally, via his past and present service on the Program Committee, the Clinical Practice Guidelines Committee and the Diversity and Inclusion Committee of the American Society of Colon and Rectal Surgeons. Videos John Migaly, M.D.Chief of Colorectal Surgery"". Dr. Migaly is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Anal Cancer, Colostomy, and Ileostomy.

Ilene S. Browner, M.D. specializes in geriatric oncology. Dr. Browner is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Endoscopy.

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Dr. Ross C. Donehower is an oncologist in the Baltimore area, caring for patients with gastrointestinal cancers. He was part of the team that developed premedications that allowed paclitaxel — a chemotherapy medication now used to treat several types of cancers — to be safely given to patients. The Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer, he serves as the director of the Hematology & Medical Oncology Fellowship Program and director of the Division of Medical Oncology at the Johns Hopkins School of Medicine. Dr. Donehower received his undergraduate degree from Hamline University and earned his M.D. from the University of Minnesota. He completed his residency at The Johns Hopkins Hospital. Dr. Donehower joined the Johns Hopkins faculty in 1980. Prior to joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate of the medicine branch and clinical pharmacology branch at the National Cancer Institute. His research interests include gastrointestinal cancers, new anticancer drug development and pharmacology. Dr. Donehower serves on the editorial boards of numerous scholarly journals, including the International Journal of Oncology. He has been recognized by the American Society of Clinical Oncology with a 2017 Excellence in Teaching Award. He is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Donehower is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Richard Battafarano, M.D., Ph.D., joins the Johns Hopkins Department of Surgery as director of the Division of General Thoracic Surgery and the first regional director of general thoracic surgery. He comes to Johns Hopkins from University of Maryland Medical System, where he was chief of the Division of Thoracic Surgery. Dr. Battafarano specializes in the treatment of benign and malignant diseases and lesions of the chest, including minimally invasive operations such as video-assisted thoracscopic surgery (VATS) for lung and esophageal cancers. He also has a special interest in treating Barretts esophagus, emphysema, mesothelioma and paraesophageal hernias. The focus of Dr. Battafaranos basic and translational research includes outcomes in the surgical management of early stage lung cancer patients with neuroendocrine histology, optimal management of lung cancer patients with mediastinal lymph node metastases, and the effect of survivin overexpression in the development of esophageal cancer. Dr. Battafarano sees patients at The Johns Hopkins Hospital and the Johns Hopkins Health Care & Surgery Centers at Green Spring Station and at White Marsh. Dr. Battafarano is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Lung Cancer, Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Gastrectomy, and Endoscopy.

Dr. Sydney Morss Dy currently practices with the Primary Care for Cancer Survivors Program at Green Spring Station. She holds a joint appointment in medicine and in oncology at the Johns Hopkins University School of Medicine. She is a professor of health policy and management at the Johns Hopkins University Bloomberg School of Public Health. Her areas of clinical expertise include cancer survivorship, internal medicine, and palliative care. For many years, she was the physician for the pain and symptom management clinic in the Cancer Center and for Hopkins' cancer case management program. Dr. Dy earned her M.D. and her M.Sc. in health services research from the Stanford University School of Medicine. She completed both a residency and a fellowship at Johns Hopkins before joining the faculty in 2001. Dr. Dy is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Lung Cancer, Angiosarcoma, Opioid Induced Constipation, and Throat Cancer.

Vikesh Singh is a gastroenterologist who specializes in pancreatology and pancreaticobiliary endoscopy. He evaluates and treats patients with inflammatory diseases of the pancreas, including acute and chronic pancreatitis and autoimmune pancreatitis as well as the complications of these diseases. After earning his medical degree from the Johns Hopkins University School of Medicine, Dr. Singh remained at Johns Hopkins to complete residency training in internal medicine. He pursued fellowship training in gastroenterology at Brigham and Women’s Hospital, and earned a master’s degree in epidemiology from the Harvard T. H. Chan School of Public Health. He then returned to Johns Hopkins, where he completed a two-year advanced endoscopy fellowship with a focus on pancreaticobiliary endoscopy. Dr. Singh has been on the faculty at Johns Hopkins since 2008, and rose to the rank of professor in 2021. His research interests include acute and chronic pancreatitis, autoimmune pancreatitis, exocrine pancreatic insufficiency, and novel methods to evaluate and treat abdominal pain. Dr. Singh is a member of the board of directors of the National Pancreas Foundation, chair of the Pancreatic Disorders Section of the American Gastroenterological Association, a councilor for the International Association of Pancreatology and a member of the inaugural medical advisory board for the Familial Chylomicronemia Syndrome Foundation. Dr. Singh is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Exocrine Pancreatic Insufficiency, Hereditary Pancreatitis, Acute Pancreatitis, Pancreatectomy, and Endoscopy.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Ivane Chua is a Colorectal Surgeon in Towson, Maryland. Dr. Chua is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Hemorrhoids, Familial Colorectal Cancer, Rectal Prolapse, Hernia Surgery, and Bladder Reconstruction.

Joseph Dirocco is a Colorectal Surgeon in Towson, Maryland. Dr. Dirocco is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Encopresis, Hemorrhoids, Bowel Incontinence, Bladder Reconstruction, and Hemorrhoidectomy.

George Apostolides is a Colorectal Surgeon in Towson, Maryland. Dr. Apostolides is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Bowel Incontinence, Rectal Prolapse, Encopresis, Ileostomy, and Hernia Surgery.

Francesco Grasso is a Colorectal Surgeon in Towson, Maryland. Dr. Grasso is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Anal Cancer, Mesenteric Venous Thrombosis, Genital Warts, Bladder Reconstruction, and Ureteroscopy.

Debashish Bose is a Surgical Oncologist and a General Surgeon in Baltimore, Maryland. Dr. Bose is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bose is currently accepting new patients.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Glioma, and Hepato-Pancreato-Biliary Surgery.

Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Cara Wilt is a Nurse Practitioner in Towson, Maryland. Ms. Wilt is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Gastroesophageal Junction Cancer, Ampullary Cancer, and Pancreaticoduodenectomy. Ms. Wilt is currently accepting new patients.

Gang Chen is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Colorectal Cancer, Myelodysplastic Syndrome (MDS), Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Chen is currently accepting new patients.

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies. Dr. Anagnostou is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Esophageal Cancer.